Clinical Trials Logo
  1. Home
  2. Sarcoma
  3. NCT03658343
  4. Details
NCT03658343 Clinical Trial

T2* MRI Analysis for Sarcoma

Sarcoma Clinical Trial

Official title:
An Exploratory, Pilot Study Evaluating T2* Imaging for Adult Sarcoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03658343
Other study ID # 201807711
Secondary ID 5P30CA086862
Status Recruiting
Phase N/A
First received
Last updated
Start date September 18, 2018
Est. completion date December 31, 2026

Study information
Verified date October 2023
Source University of Iowa
Contact Bryan G. Allen, MD, PhD
Phone (319) 356-3693
Email bryan-allen@uiowa.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

T2* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.

Recruitment information / eligibility
Status Recruiting
Enrollment 15
Est. completion date December 31, 2026
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - pathologically confirmed Sarcoma, by biopsy or excision - prescribed radiation therapy as per standard of care - treatment to begin within 5 weeks after surgery or biopsy - ECOG 0, 1, or 2 - ability and willingness to provide informed consent Exclusion Criteria: - < 18 years of age

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• T2* Imaging
T2* imaging sequences for MRI

Locations
Country Name City State
United States Holden Comprehensive Cancer Center Iowa City Iowa

Sponsors (3)
Lead Sponsor Collaborator
Bryan Allen Holden Comprehensive Cancer Center, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change in ferric iron levels detected by T2* MRI Change from baseline in Fe3+ iron levels baseline and 8 weeks
Secondary Change in ferrous iron levels detected by T2* MRI Change from baseline in Fe2+ iron levels Baseline and 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT04535713 - GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Phase 2
Completed NCT03521531 - Burden and Medical Care of Sarcoma in Germany
Completed NCT02496520 - Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults Phase 1/Phase 2
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT04052334 - Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Phase 1
Completed NCT01593748 - A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Completed NCT01879085 - Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Phase 1/Phase 2
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2